Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Osimertinib - AstraZeneca

Drug Profile

Osimertinib - AstraZeneca

Alternative Names: [11C]AZD9291; [11C]osimertinib; AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 19 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly and Company; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Princess Margaret Hospital (University of Toronto); Singapore Clinical Research Institute; Sunnybrook Health Sciences Centre; University of California at San Francisco
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Glioblastoma; Meningeal carcinomatosis
  • No development reported Solid tumours

Most Recent Events

  • 19 Nov 2020 AstraZeneca anticipates regulatory decisions for Non-small cell lung cancer (Adjuvant therapy) in China and in the US (PO), in the first half of 2021
  • 19 Nov 2020 AstraZeneca completes regulatory application for Non-small cell lung cancer (Adjuvant therapy) in China (PO), prior to November 2020
  • 01 Nov 2020 Preregistration for Non-small cell lung cancer (Adjuvant therapy) in China (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top